← Leaderboards
Charles A. Scanga
University Of Pittsburgh At Pittsburgh
$10,882,031
Attributed
$16,585,682
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,585,682 · 4
By mechanism
R01$16,585,682 · 4
Top collaborators
- Lishomwa C Ndhlovu8 shared
- Shelby L Oconnor8 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joanne L. Flynn$43,717,509
- Philana Ling Lin$10,232,778
- Joshua T. Mattila$2,064,710
- Eric Joseph Rubin$20,208,402
- Fernando Holguin$10,342,142
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsCo-InfectionTuberculosisMycobacterium TuberculosisInfectionMacacaImmunityInsightRisk FactorsAdultGlobal HealthNonhuman PrimateChildhoodImmunocompromised HostPersonsHiv InfectionsAnimal ModelTuberculosis VaccinesMacaca FascicularisImmunePreventVaccinationPredispositionMortality
Grant awards (18)
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$784,938
R01 · FY2025 · AI · contact PI
Preventing TB with intravenous BCG in SIV-infected macaques$765,413
R01 · FY2025 · AI · contact PI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$793,149
R01 · FY2024 · AI · contact PI
Preventing TB with intravenous BCG in SIV-infected macaques$788,364
R01 · FY2024 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,200,666
R01 · FY2023 · AI · contact PI
Preventing TB with intravenous BCG in SIV-infected macaques$1,129,254
R01 · FY2023 · AI · contact PI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection$826,203
R01 · FY2023 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,216,647
R01 · FY2022 · AI · contact PI
Preventing TB with intravenous BCG in SIV-infected macaques$792,599
R01 · FY2022 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,213,831
R01 · FY2021 · AI · contact PI
Preventing TB with intravenous BCG in SIV-infected macaques$772,812
R01 · FY2021 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,218,191
R01 · FY2020 · AI · contact PI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents$1,301,851
R01 · FY2019 · AI · contact PI
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques$740,051
R01 · FY2019 · AI · contact PI
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques$751,157
R01 · FY2018 · AI · contact PI
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques$757,751
R01 · FY2017 · AI · contact PI
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques$754,049
R01 · FY2016 · AI · contact PI
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques$778,756
R01 · FY2015 · AI · contact PI